1 |
Fuller SJ, Edmunds NS, McGuffin LJ, Hardyman MA, Cull JJ, Alharbi HO, Meijles DN, Sugden PH, Clerk A. MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins. Biochem J 2021;478:2121-43. [PMID: 34032269 DOI: 10.1042/BCJ20210003] [Reference Citation Analysis]
|
2 |
Berecz T, Yiu A, Vittay O, Orsolits B, Mioulane M, Dos Remedios CG, Ketteler R, Merkely B, Apáti Á, Harding SE, Hellen N, Foldes G. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy. ESC Heart Fail 2021. [PMID: 34931757 DOI: 10.1002/ehf2.13756] [Reference Citation Analysis]
|
3 |
Borges GSM, Lages EB, Sicard P, Ferreira LAM, Richard S. Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies. Front Cardiovasc Med 2021;8:690533. [PMID: 34277738 DOI: 10.3389/fcvm.2021.690533] [Reference Citation Analysis]
|
4 |
Wu BB, Leung KT, Poon EN. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. Int J Mol Sci 2022;23:1912. [PMID: 35163838 DOI: 10.3390/ijms23031912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|